XML 134 R116.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 29, 2019
USD ($)
[1]
Sep. 29, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jul. 01, 2018
USD ($)
Apr. 01, 2018
USD ($)
Dec. 29, 2019
USD ($)
segments
Dec. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Operating income from continuing operations $ 138,248 $ 78,660 $ 91,735 $ 53,330 $ 115,683 $ 80,202 $ 88,064 $ 39,935 $ 361,973 $ 323,884 $ 295,615
Number of Operating Segments | segments                 2    
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 2,883,673 2,777,996 2,256,982
Interest and other expense (income), net                 124,831 66,201 (1,103)
Income from continuing operations before income taxes $ 65,296 $ 63,254 $ 71,827 $ 36,765 $ 79,429 $ 78,041 $ 71,708 $ 28,505 237,142 257,683 296,718
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market                 31,200 21,400  
Acceleration of executive compensation                 7,700    
Diagnostics [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Operating income from continuing operations                 189,330 153,196 146,862
Revenue from Contract with Customer, Excluding Assessed Tax                 1,137,512 1,084,785 678,523
Discovery & Analytical Solutions [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Operating income from continuing operations [2]                 238,331 230,481 205,259
Revenue from Contract with Customer, Excluding Assessed Tax                 1,746,161 1,693,211 1,578,459
Corporate [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Operating income from continuing operations [3],[4]                 (65,688) (59,793) (56,506)
Particular Diagnostics Case [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Legal Fees                 100 200  
Particular Discovery & Analytical Solutions Case [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Legal Fees                 2,200 5,300 2,700
Product [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 2,017,042 1,935,493 1,477,414
Product [Member] | Diagnostics [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 962,180 924,594 536,086
Product [Member] | Discovery & Analytical Solutions [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 1,054,862 1,010,899 941,328
Service [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 866,631 842,503 779,568
Service [Member] | Diagnostics [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 175,332 160,191 142,437
Service [Member] | Discovery & Analytical Solutions [Member]                      
Schedule of Segment Reporting Information, by Segment [Line Items]                      
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 691,299 $ 682,312 $ 637,131
[1] The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy
[2]
Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $2.2 million, $5.3 million and $2.7 million for fiscal years 2019, 2018 and 2017, respectively. Legal costs for significant litigation matters in the Company's Diagnostics segment were $0.1 million and $0.2 million for fiscal years 2019 and 2018, respectively.
[3]
(2) 
Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019.
[4]